First American Trust FSB Purchases 24,399 Shares of Medtronic PLC $MDT

First American Trust FSB lifted its position in Medtronic PLC (NYSE:MDT) by 24.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 125,324 shares of the medical technology company’s stock after purchasing an additional 24,399 shares during the period. First American Trust FSB’s holdings in Medtronic were worth $12,039,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Artisan Partners Limited Partnership raised its holdings in Medtronic by 2.6% in the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after purchasing an additional 31,314 shares in the last quarter. CSM Advisors LLC raised its holdings in Medtronic by 13.2% in the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after purchasing an additional 33,167 shares in the last quarter. SageView Advisory Group LLC raised its holdings in Medtronic by 164.8% in the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after purchasing an additional 15,062 shares in the last quarter. Madison Asset Management LLC boosted its position in shares of Medtronic by 15.0% in the 4th quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock worth $18,752,000 after purchasing an additional 25,527 shares in the last quarter. Finally, Bleakley Financial Group LLC boosted its position in shares of Medtronic by 17.8% in the 3rd quarter. Bleakley Financial Group LLC now owns 87,313 shares of the medical technology company’s stock worth $8,316,000 after purchasing an additional 13,177 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on MDT shares. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Argus dropped their price target on Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Stifel Nicolaus set a $80.00 price target on Medtronic in a research report on Wednesday, June 3rd. Weiss Ratings cut Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. Finally, Sanford C. Bernstein dropped their price target on Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research report on Thursday, June 4th. Seventeen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $99.00.

Medtronic Stock Down 2.1%

Shares of Medtronic stock opened at $80.27 on Thursday. The stock has a market capitalization of $103.06 billion, a PE ratio of 21.52, a price-to-earnings-growth ratio of 2.00 and a beta of 0.58. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The company has a 50-day simple moving average of $81.10 and a two-hundred day simple moving average of $91.60.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.01. The business had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, June 26th. This is an increase from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.6%. Medtronic’s dividend payout ratio is currently 76.14%.

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.26% of the stock is currently owned by insiders.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received FDA clearance for an updated Nellcor pulse oximetry system, which should help its monitoring portfolio and improve performance across diverse patient groups. Medtronic gets FDA nod for updated pulse oximetry system
• Positive Sentiment: The company earned CE mark approval for its Stealth AXiS robotic platform in ENT surgery, expanding its reach in Europe and supporting future procedure volume. Medtronic earns CE mark for Stealth AXiS robot platform in ENT surgery
• Positive Sentiment: Investor sentiment toward healthcare has improved as money rotates out of tech and into defensive sectors, which can help MDT relative to the broader market. As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
• Positive Sentiment: Recent commentary has highlighted Medtronic as attractively valued at about 14x forward earnings with a 3.5% dividend yield and steady fiscal 2027 guidance. Is Medtronic Stock a Buy at 14x Forward Earnings?
• Neutral Sentiment: Analysts remain broadly constructive, but some recent price-target cuts suggest expectations have been reset after the latest earnings update.
• Neutral Sentiment: MarketWatch noted Medtronic underperformed some peers despite gains, indicating investors are still favoring stronger near-term names in the sector. Medtronic PLC stock underperforms Tuesday when compared to competitors despite daily gains
• Negative Sentiment: EVP Harry Skip Kiil sold 4,189 shares, a transaction that can modestly weigh on sentiment even if it may be routine. Harry Skip Kiil insider transaction
• Negative Sentiment: Investors also appear focused on margin pressure risks from tariffs and mix shifts, which could limit upside despite steady growth. Is Medtronic Stock a Buy at 14x Forward Earnings?

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).